Canada markets closed

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.37+0.11 (+1.76%)
At close: 4:00PM EDT
Sign in to post a message.
  • W
    Whiskey
    Clinical Project Manager position appears to be filled, it dropped off the HTBX Careers web page today.
  • M
    Michael
    Heat has updated their website

    HS-110 Phase II complete
    HS-130 Phase I almost complete
    PTX-35 Phase I almost complete

    No updates yet to the Clinical Trial webpages

    Added their September pdf presentation
  • M
    Michael
    For the doubters. It's all about the contract manufacturing now. Even if HS-110 gets to phase III in 2022 or later and out of phase III in 2025-26 there won't be any revenues from it for at least three years. It's all about the contract manufacturing at this point.

    Scorpion Biological Services is located in the biotech and life sciences hub of San Antonio, Texas. We are a fast-growing contract research company with plans for expansion to our laboratories and the addition of GMP manufacturing.

    Scorpion – Biological Services
    https://scorpionbio.com/
    Scorpion – Biological Services
    scorpionbio.com
  • D
    Dale
    The shorts on this board are misleading you on many fronts including bankruptcy.
    They have $122 million in the bank and all 5 analysis that cover this stock rate it a buy with a price target of $20.67. There are NO sell analysis and NO hold analysis only BUY analysis. The book value is $5.23 per share with very little debt. Last quarter their cash reserves went down by only $10 million and if this rate of spending continued, they would have almost 3 years of funds in the bank. The shorts make wild statements and no proof to back up their comments.
    All of the above numbers can be found on their balance sheet and income statement so shorts don’t argue with me, I’m using the company’s audited numbers.
  • T
    TIMON
    Well, nice close.
    Be ready tomorrow morning 11am for the conference. We can expect a PR before Market open. Good luck everybody
  • A
    ARC
    DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the launch of its wholly-owned subsidiary, Skunkworx Bio, Inc. (“Skunkworx”), focused on the development of a drug discovery paradigm to enable rapid drug development.
  • D
    Dave
    Question for longs: Is this a cart before the horse initiative? Here's the PR from yesterday:

    "The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials."

    The various infectious disease/biological threat programs are in pre-clinical development so we don't have much to offer at present. The company can roll out a structure but without a defense it may take a long time to implement.

    I am long here but I am not sure about this plan in the short term(1-2 years).
  • s
    sunny
    HS110 Phase 2 completed - demonstrate signals of efficacy in NSCLC patients.

    Plan to discuss Phase 3 registration with FDA as well as POTENTIAL PARTNERS!!!

    Line Extension strategy to include additional indications that have been approved for PD-L1 Therapies!!!

    https://ir.heatbio.com/all-sec-filings/content/0001553350-21-000751/0001553350-21-000751.pdf
  • A
    ARC
    Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announces it has commenced development of a new biosecurity/biodefense initiative. The Company also announces it has formed an advisory board to support this initiative. Joining the new advisory board are David Lasseter, Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction, and Former US Representative Jack Kingston.
  • P
    Paul
    Bidens $3.5t dollar budget has billions ear mark for biosecurity.
  • A
    ARC
    CEO Jeff Wolf will host a conference call on Thursday, September 2nd at 11:00 A.M. Eastern Time on company activities
  • r
    raj
    why is this stock going down
  • A
    Andrew
    Wish people trying to sell these other stocks would go away they have nothing for the board just like IVO
  • P
    Paul
    HS-410 is going into phase 2
  • D
    Dr. Phil
    Feeling bullish today at 11 am CC. CEO Wolf is expected to highlight coming Phase III FDA filing at newly acquired San Antonio facility, successfully completed Phase ii, future of company in defending against biological threats, along with introducing newly supported advisory board seats.
  • k
    karim
    I bought this stock when was 0.70$ so after reverse split it’s 7$ diluted . Get out before it goes back to 0.70$
  • I
    IVO
    @ Edward I love the fact you are positive after 1 good day and the rest of the year bad figures ! You can only be happy if heat adds another 80 pro recover their losses
  • A
    ARC
    B. Riley lowers HEAT Biologics PT to $15 from $20. Keeps buy rating.
  • M
    Michael
    $HTBX there is a rumor that people who post false comments about CEOs and about companies that are knowingly false will soon be open to prosecution. Apparently cyber tracing methods of finding out the true owners of accounts that post knowingly false and malicious info attacking people and companies have made huge leaps recently. Damage and punitive damages could be huge. It appears that in the case of attacks on companies that hve secret dealings with the military, FISA warrants can be obtained so the people posting lies that can hurt national security initiatives can be investigated without their knowledge. It’s about time!
  • K
    Kirtz
    5000% tomorrow